FDA approved the CustomFlex Artificial Iris made by HumanOptics for adults or children whose iris is completely missing or damaged due to injury, surgery, or a rare genetic disorder.
Pulmonx released positive one-year-results from the LIBERATE pivotal trial of the Zephyr Endobronchial Valve, which shows the study met all primary and secondary endpoints.
StimGuard scores a CE mark for its overactive bladder system and becomes the latest company to have a commercialized product in the neuromodulation space.
Medtronic has initiated a clinical study to see if its Resolute Onyx DES can treat bifurcation lesions, which account for about 20% of all percutaneous coronary interventions.
Ancora Heart said FDA has approved an expansion of the company’s feasibility study to evaluate the AccuCinch Ventricular Repair System designed for the treatment of heart failure and functional mitral regurgitation (FMR).
The TMVR market continues to thrive, but Neovasc is having problems making a significant impact in the promising space, according to its most recent earnings report.
The market for minimally invasive glaucoma surgery devices is expected to pop for the foreseeable future.
GI Dynamics has been increasing its activity lately by raising offerings and getting favorable data published for its EndoBarrier, an obesity treatment device.
InVivo Therapeutics presented complete six-month results from its INSPIRE study, which was temporarily halted after three patients died during the study last year.
LivaNova topples Wall Street consensus on sales and EPS in its first quarter, but sees dip in shares.
Nearly 11 years after being spun off from Medtronic, Inspire Medical is going public through a $75 million IPO.
Boston Scientific received FDA approval for the Vercise technology to treat Parkinson's disease in December of 2017, based on the results of the INTREPID trial data.